Topical Application of Tacrolimus Ointment Did Not Alter the Cutaneous Pigmentation of Yucatan Micropigs

Abstract

Tacrolimus is a potent immunosuppressant marketed for the prevention of rejection in liver and kidney transplantation. Topical tacrolimus has been shown to be effective in the treatment of atopic dermatitis, a disease with an immunologic basis, and is currently being developed for this indication. The objective of the current study was to determine whether repeated topical application of tacrolimus ointment could result in hypopigmentation at the application site(s). Each of 10 Yucatan miniature pigs received topical application of 0.03%, 0.1%, and 0.3% tacrolimus ointment, positive control (a combination of 2% 4-hydroxyanisole and 0.01% all-trans-retinoic acid, 4-HAArRA), and a negative control (vehicle placebo) to five test sites (approximately 12.5 cm²) along either side of the dorsal midline (10 sites per animal). Tacrolimus and controls were randomly assigned to the test site on each animal and were applied unoccluded twice daily for 8 weeks at a dose volume of 0.1 ml per site for tacrolimus and vehicle control and 0.025 ml per site for the positive control. Topical application of tacrolimus ointment in concentrations of up to 0.3% for 8 weeks had no effect on the cutaneous pigmentation of Yucatan miniature swine. In contrast, the application of 4-HAArRA produced a statistically significant (P<.05) induction of hypopigmentation from week 4 through the end of the study application.

Keywords

FK506 Ointment Hypopigmentation Micropigs Tacrolimus Ointment

References

Abu-Elmagd, K. , D. Van Thiel , B. V. Jegasothy , C. D. Ackerman , S. Todo , J. J. Fung , and T. E. Starzl . 1991. FK506: A new therapeutic agent for severe recalcitrant psoriasis. Transplant. Proc. 23:3322–3324.

Aoyama, H. , N. Tabita , M. Tanaka , Y. Uesugi , and H. Tagami . 1995. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. Br. J. Dermatol. 133:494–496.

Bird, J. , and J. Montana . 1996. New approaches to atopic dermatitis. Exp. Opin. Invest. Drugs 5:1173–1180.

Draize, J. H. , G. Woodward , and H. O. Calvary . 1944. Methods for the study of irritation and toxicity of substances applied to the skin and mucous membranes. J. Pharmacol. Exp. Ther. 82:377–390.

Ehlayed, M. S. 1996. Atopic dermatitis: Immunopathology and therapeutic implications. J. Bahrain Med. Soc. 8:43–51.

Lauerma, A. I. , and H. I. Maibach . 1994. Topical FK506—clinical potential or laboratory curiosity? Dermatology 188:173–176.

Nair, X. 1993. Combination of 4-hydroxyanisole and all-trans-retinoic acid produces synergistic skin depigmentation in swine. J. Invest. Dermatol. 101: 145–159.

Nair, X. , and K. Tramposh . 1991. The Yucatan miniature swine as an in vivo model for screening skin depigmentation. J. Dermatol. Sci. 2:428–433.

Nakagawa, H. , T. Etoh , Y. Ishibashi , Y. Higaki , M. Kawashima , H. Torü , and S. Harada . 1995. Effects of tacrolimus (FK506) ointment for facial atopic dermatitis. Allergy 50:368.

10.

Sambuco, C. P. 1985. Miniature swine as an animal model in photodermatology: Factors influencing sunburn cell formation. Photodermatology 2: 144–150.

11.

Sambuco, C. P. , and D. Forbes . 1986. Miniature swine in photodermatology. In Swine in biomedical research, M. E. Tumbleson , ed. 681–687. New York: Plenum Publishing.

12.

Sambuco, C. P. , P. D. Forbes , R. E. Davies , and F. Urbach . 1987. Protective value of skin tanning induced by ultraviolet radiation plus a sunscreen containing bergamot oil. J. Soc. Cosmet. Chem. 38:11–19.

13.

Shurpaik, J. , E. Abel , E. Bauer , M. Brown , L. Drake , R. Frienkel , G. Guzzo , J. Koo , N. Lovine , N. Lowe , C. McDonald , D. Margolis , M. Stiller , B. Wintroub , C. Bainbridge , S. Evans , S. Hilss , W. Mierlowsky , C. Winslow , and J. Birnbawn . 1997. Cyclosporineas maintenance therapy in patients with severe psoriasis. J. Am. Acad. Dermatol. 36:423–432.

14.

United States Multicenter FK506 Liver Study Group. 1994. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N. Engl. J. Med. 331: 1110–1115.

15.

Woodle, E. S. , J. R. Thistlewaite , J. A. Gordon, et al. 1996. A multicenter trials FK506 (tacrolimus) therapy in refractory acute renal allograft rejection: A report of the tacrolimus kidney transplantation rescue study group. Transplantation 62:594–599.